Wellgistics Health, Inc. has launched its diabetes drug Brenzavvy® to its pharmacy network, targeting the $16 billion SGLT-2 inhibitor market in the US. The company uses its EinsteinRx™ AI platform to assist pharmacists with patient education, aiming to reduce out-of-pocket costs and enhance patient access. This launch establishes a new model for reformulated drug introductions in the market.

WGRX

<p>Wellgistics Health, Inc. has launched its diabetes drug Brenzavvy® to its pharmacy network, targeting the $16 billion SGLT-2 inhibitor market in the US. The company uses its EinsteinRx™ AI platform to assist pharmacists with patient education, aiming to reduce out-of-pocket costs and enhance patient access. This launch establishes a new model for reformulated drug introductions in the market.</p>

Wellgistics Health Launches Diabetes Drug Brenzavvy®